The Birch Allergoid, Tyrosine Adsorbate, Monophosphoryl Lipid A (POLLINEX â Quattro Plus 1.0 ml Birch 100%) is an effective, well-tolerated short course subcutaneous immunotherapy. We performed 2 phase II studies to determine its optimal cumulative dose.
| INTRODUCTION
Efficacy of allergen immunotherapy (AIT) is related to the cumulative dose (CD) of the allergen or allergoid [1] [2] [3] [4] [5] [6] [7] [8] for symptom control and immunological changes. No consensus exists on the best method to select the optimal effective and tolerable CD. Failure to select an effective dose is a major cause for the high failure rate of phase III pivotal studies. 9 For AIT dose selection, the European Medicines Agency (EMA) suggests the use of allergen or pollen provocation tests, 10 with standardized titrated quantities of allergen used to elicit eye and/or nasal symptoms and ideally to select subjects with a threshold symptom score for a positive test. Efficacy of each dose regimen can be assessed without the influence of variable allergen exposure, in contrast to "field" studies with seasonal pollen counts 11, 12 or perennial allergens. 13 Choice of effective CD is often limited by systemic reactions such as anaphylaxis. 14 Dose regimens use tiny individual doses administered over a prolonged time, or hypoallergenic formulations such as allergoids, 15 peptides and recombinants [16] [17] [18] to allow quicker updosing and earlier achievement of CDs.
Dose response curves in studies of AIT products to date are either monotonic (exponential), 8, 19 or nonmonotonic (higher dose less effective than the lower). 7, 20 In either case, the ideal study design comprises a wide range of CDs and sufficient subjects to allow the dose response curve to be tested. Limitations of recent failed studies include restricted range of CDs, too few CDs or the use of pairwise comparisons of each CD with placebo.
Multiple Comparison Procedure and Modeling (MCP-Mod) 21 is an alternative method of analysis of dose response, best used with 4-10 active doses and 5-fold to 10-fold increases in CDs. It enables testing of the shape of the dose response curve (see Appendix S1) and controls the type 1 error rate, avoiding the false detection of a dose response. It has been qualified by the Committee for Medicinal Products for Human Use (CHMP) 22 and meets many of the International Committee on Harmonisation E4 requirements. 23 The POLLINEX â Quattro plus 1.0 mL, subcutaneous immunotherapies (SCITs) currently offer short courses of injections that are effective and well tolerated. [24] [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] They include POLLINEX â Quattro Plus 1.0 mL Birch 100% (PQBirch). Pollinex Quattro SCITs are listed in the current AIT European Academy of Allergy and Clinical Immunology (EAACI) guidelines with grade IA recommendation based upon data from double-blind placebo-controlled trials. [24] [25] [26] [31] [32] The PQBirch, currently available on a named patient basis, is under development for full registration. 18, 35 We describe the results from 2 dose selection studies in which PQBirch was tested in subjects with seasonal allergic rhinoconjunctivitis due to birch pollen, with the aim of establishing a useful study design and selecting an optimal CD for use in phase III trials.
| METHODS

| Study design
Two randomized, double-blind, parallel group, multicentre studies were conducted in Germany, Austria (PQBirch203 and PQBirch204) and Poland (PQBirch203 only) between September 2013 and February 2016, outside birch and tree pollen season. PQBirch203 used a limited range (600 to 13 600 standardized units [SU] and 4 CDs for comparison). PQBirch204 was placebo-controlled with a wider range of CDs (up to 27 300 SU). Studies were conducted in accordance with Good Clinical Practice guidelines and the Declaration of Helsinki. The protocols were approved by the responsible competent and ethical bodies in each participating country. All subjects provided written informed consent before any study activity.
Conjunctival Provocation Test (CPT) 36 (see Appendix S2) was performed at the first visit and repeated at subsequent visits to confirm eligibility and establish the baseline score prior to randomization.
Study treatment was administered, and post-treatment CPT was performed 3-4 weeks (+/À3 days) after the last injection. In both studies, primary endpoint was change in baseline to post-treatment TSS recorded following CPT with the allergen concentrations eliciting the TSS ≥6 adjusted for reference eye score at the confirmatory CPT. The secondary endpoint for both studies was number of additional allergen concentration steps required to elicit a positive CPT post-treatment.
In PQBirch203, a further secondary endpoint was amount of Immunoglobulin G (IgG), IgG4 and IgE before and after treatment, whilst in PQBirch204, allergen-specific IgE was recorded and descriptively analysed.
| Study subjects
Eligible male and female subjects were 18-60 years of age, with a clinical history of moderate to severe symptoms of seasonal allergic rhinoconjunctivitis due to birch pollen exposure that required repeated use of antihistamines, nasal steroids and/or leukotriene modifiers for at least the last 2 years. Additionally, they had a positive skin prick test for birch ≥3 mm, a birch-specific IgE ≥class 2 (by an ImmunoCap test) and a positive CPT at screening (Total Symptom Scorev [TSS] ≥6, adjusted for reference eye score).
Key exclusion criteria were the presence of symptoms upon exposure to any other allergens that were unavoidable during the trial period, moderate to severe asthma, AIT within the past 5 years, completed or ongoing anti-IgE therapy, pregnancy, chronic or malignant diseases, drug or alcohol abuse and psychiatric disorders.
| Sample size estimation
| PQBirch203 study
It was calculated that 32 subjects in each dose group (128 subjects in total) would have 89% power to detect a difference in means of WORM ET AL. | 1813 À0.9 assuming a common standard deviation of 1.0 (t test with a 0.025 two-sided significance level). Assuming a 10% dropout rate, the study included 35 subjects per dose group.
| PQBirch204 study
The sample size was calculated to allow for sufficiently accurate estimation of the median effective dose (ED 50 ). Assuming equal baseline values, and with a mean post-treatment TSS in the placebo group of 6.1 points, a difference of 1.34 in mean post-treatment TSS change from baseline signified a 22% improvement.
Simulations revealed that, with an assumed ED 50 of 1095 SU, and an assumed effect of 3.0 for the 27 300 SU dose, a sample size of 45 subjects in each dose group would yield a 90% confidence interval (CI) of length 2440 SU for the ED 50 . Only a reconfirmed test could provide a baseline TSS and allergen concentration.
| The CPT allergen provocation test
Four eye symptoms after challenge with the allergen or negative control were recorded as subject and investigator reported outcomes (mixed patient-reported outcomes measures [PROMs]) using a severity rating scale as follows: 0 = absent, 1 = mild, 2 = moderate and 3 = severe. Subjects independently scored the eye symptoms of itching and irritation, followed by co-assessment of eye tearing in conjunction with the investigator and scoring of eye redness by the investigator independent of the subject. 36 This questionnaire (Culture-Independent Assessment of the Conjunctival Provocation Test [CIA-CPT©]) was conducted 10 minutes after application of negative control or allergen.
The CPT was only conducted on subjects with no visible and/or reported eye symptoms or complaints on the day of the assessment and no current antihistamine treatment.
| Study medications and treatment schedules
PQBirch was administered as 6 subcutaneous injections at 7 (+/-) 1day intervals.
In the PQBirch203 study, subjects received 1 of 4 CDs (600, 1550, 5100 or 13 600 SU), each achieved with individual injected doses of 1.0 mL containing 3500, 2000, 800, 300 or 150 SU of PQBirch or placebo. Subjects enrolled in the 13 600 SU dose group received 6 injections of the study drug, whilst subjects enrolled in the 600, 1550 and 5100 SU dose groups received 2 initial injections of placebo (1.0 mL of 2% w/v L-tyrosine) to maintain the blind, followed by 4 injections of study drug.
In the PQBirch204 study, subjects received either placebo or 1 
| Statistical analysis
| Study PQBirch203
The analysis of the primary efficacy variable (change from baseline to post-treatment in TSS following CPT) was performed using an analysis of covariance (ANCOVA) with dose group and grade of birch pollen sensitivity as class variables and the baseline TSS as covariate. An a priori strict semihierarchical test procedure was applied to the hypotheses starting with the highest to the lowest dose, using a Bonferroni adjustment to control the type 1 error rate. Thus, the 2 highest CDs (13 600 and 5100 SU) were first tested against the lowest dose (600 SU) in parallel, using a significance level of alpha/2 (0.025).
The next lower dose was tested against the next lowest dose only if both tests were statistically significant. 
The primary efficacy analysis was conducted on the modified Full
| Study PQBirch204
The primary efficacy variable was the change in TSS following CPT, from baseline to post-treatment, using the mFAS.
The MCP-Mod methodology was used to test for a dose response trend using the placebo, and 5100, 15 000, 20 100 and 27 300 SU treatment arms, and to estimate the dose response shape. The multiple contrast tests for the dose response were calculated based on an ANCOVA with dose group as class variable and the baseline TSS as covariate (see Appendix S1). 
| RESULTS
In the PQBirch203 study, 174 subjects were enrolled and screened, and 149 were randomized to receive study medication, including 37 randomized into dose group 13 600 SU, 37 randomized into dose group 5100 SU, 36 randomized into dose group 1550 SU, and 39 randomized into dose group 600 SU. The main reason for ineligibility was violation of the inclusion or exclusion criteria. One subject requested to be withdrawn, and 8 subjects were not randomized as the recruitment target had been achieved.
In the PQBirch204 study, 461 subjects were enrolled and screened, and 371 were randomized to receive study medication, including 1 subject who had been randomized into the 27 300 SU dose group despite being a screening failure and was not treated. Demographic and baseline data were analysed for the mFAS which included 143 subjects in the PQBirch203 study and 370 subjects in the PQBirch204 study (see Table 1 ). Females accounted for 39%-66% of the subjects; ages ranged from 18 to 59 years. The primary analysis set was the mFAS for both studies.
| PQBirch203 results
The difference in TSS change from baseline to post-treatment was 1.88 (P = .0019) between the 13 600 SU and 600 SU dose groups and 1.01 (P = .0919) between the 5100 SU and 600 SU dose groups, which confirms a significant dose response. No further T A B L E 3 Multiple Comparison Procedure and Modeling pooled analysis PQBirch203 and PQBirch204, estimated differences and improvements to placebo from linear in log dose response curve (Per Protocol Set) Figure S1 ).
| PQBirch204 results
The MCP-Mod analysis (mFAS) confirmed the statistically significant dose response for all 3 candidate models (P < .0011 to .0031, see Table 2 ). As a measure of potency of the PQBirch, the averaged model estimated the ED 50 to 2723 SU. The linear in log-dose model showed the best fit (see Table 2 and Figure 1 ). Similar curves were estimated with the FAS and PPS.
Similar efficacy was seen with nearly identical CDs when administered over 4 or 6 weeks (or injections).
| Combined results of PQBirch203 and PQBirch204
Pooling of the data of the 2 studies increased the number of CDs, enabled increased precision in estimation of the dose response curve and its CI and showed the close correspondence of the mean values from the studies.
Whilst the same MCP-Mod methodology was deployed, the PPS was used to illustrate the relative and absolute differences between the CDs and the placebo. The linear in log-dose model for the dose response curve is shown in Figure 2 . The estimated relative and absolute differences with respect to change in TSS from baseline and to post-treatment TSS are shown in Table 3 . The highest CD of 27 300 SU achieved an absolute difference from placebo of 1.91 and a percentage difference of 32.3% in the posttreatment TSS.
| Allergen concentration required to elicit a positive CPT post-treatment in the PQBirch203 and 204 studies
In both studies, approximately 50% of subjects on active doses (≥1500 SU) required at least 1 further CPT concentration of allergen post-treatment to achieve a TSS of ≥6 (see Figure 3 ). There were in PQBirch203; 0 subjects on 600 SU CD who failed to achieve a TSS >6 with the highest CPT allergen concentration, 2 subjects with 1550 SU, 1 subject with 5100 SU and 1 on 13 600 SU. With the PQBirch204 study, 1 subject with placebo failed to achieve a TSS >6
with the highest CPT allergen concentration, 0 on either 5100 or 5000 SU, 1 on 15 300 and 2 with 15 000 SU, 1 on 20 100 and 1 on 27 300.
| Safety
| Results of PQBirch203 and 204 studies combined
A summary of subjects with treatment-emergent adverse events (TEAEs) across all dose groups is presented in Table 4 . Considering both PQBirch203 and PQBirch204, the percentage of TEAEs occurring with each injected dose was over 50% in all dose groups compared with 15%-17% in the placebo group, but there was no dose relationship (see Figure S2 ).
Of specific interest, the compliance for all the CDs in both studies was >85% (see Figure S3 ).
| DISCUSSION
In order to test the "shape" of the dose response curve, we confirmed the need to study a sufficient number and range of CDs with enough subjects. In the PQBirch203 study, the range of CDs was insufficient to determine the optimal dose. Increasing the CDs to include an over For selection of a therapeutic dose of AITs, it should be possible to use either allergen or pollen "challenge" studies, as advised by the EMA. 10 The CPT used in the PQBirch203 and PQBirch204 studies was first used to demonstrate efficacy of AIT by Noon in 1911. 37 It has been used to provide a diagnostic of specific allergy 38 and developed to provide a standardized method of allergen challenge suitable for dose selection studies. [39] [40] [41] Despite differences in how CPT is performed, all methods use a standard range of titrated allergen concentrations applied to the conjunctiva and PROMs. The CIA-CPT© uniquely allows both subject and investigator to contribute to scoring symptoms (a mixed PROM), and the test-retest reliability has been investigated in a pilot methodological trial. 36 Studying subjects individually avoids collusion and follows best practice for PROMs. In many aspects, CPT resembles the nasal provocation test, 42 as both tests directly add a known concentration of allergen to a responsive mucosa surface unlike pollen exposure intensity which varies. Both methods show concordance of symptom scores, 43 and post-AIT CPT results predict the efficacy of therapy during pollen seasons. 44 In PQBirch204, the shape of the dose response curve showed that the highest dose of 27 300 SU was approaching a "plateau" (Figures 1 and 2) . Nonmonotonic curves may occur with a sublingual immunotherapy (SLIT) and allergoid house dust mite SCIT. 7, 8 Further assurance about the reproducibility of this method of analysis is confirmed by the overlapping of the mean TSS scores from the PQBirch203 on the PQBirch204 MCP-Mod dose response curves.
The presentation of results as absolute and percentage differences between placebo and active treatment (see Table 3 ) is of particular value given the reported magnitude of the placebo effect in SCIT (15%-60%). 45 In the analysis of pooled data for this study, the placebo effect was 46% of the total change with the highest therapeutic dose.
An advantage demonstrated for allergoid SCIT was that the CD is more important in determining efficacy than the number of or time taken for injections, for example, 6 is no better than 4.
The TEAEs reported were mainly local, mild, related to injectionsite reactions and short-lived (see Table 4 ). Finally, there was high compliance with all CDs (see Figure S3 ).
In summary, CPT combined with MCP-Mod and a wide range of CDs provides an effective means of selecting an optimal dose regimen for a SCIT product. in IgE and a rise in the IgG4/IgE ratios with dose (see Figure S1 ).
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